Amira Files to Start Clinical Trial

9/27/10

San Diego-based Amira Pharmaceuticals, the developer of treatments for lung diseases, said today it has filed an application to the FDA to start clinical trials of a new drug for fibrotic disorders. The company is seeking to run tests in healthy volunteers on AM152, an experimental blocker of a target called LPA1.

Luke Timmerman is the National Biotech Editor of Xconomy. E-mail him at ltimmerman@xconomy.com Follow @

Next Post

Related Topics

Related Posts

    

Xconomy Events Across the Network

The Napa Summit: Keeping America Growing

San Francisco · 6/7/12

More Xconomy Events

Xconomy’s Most Popular

  1. Biotech IPOs Start to Show Some Modest Signs of Life
  2. ASCO Preview: Eight Cancer Drugs to Watch at the Big Show
  3. Hey, Silicon Valley: Wake Up and Smell the Robots
  4. From MIT Entrepreneur to Tea Party Leader: The Thomas Massie Story
  5. Announcing Xconomy’s Napa Summit: Keeping America Growing

Xconomy on Demand

Did you miss something? Don't despair…

Xconomy offers a number of ways to subscribe for free!

Subscribe Now
IDG Tech Network
Protected by Mozy
Eventbrite - events made easy

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.

© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Site produced by Andrew Koyfman with design from Rob Hunter.